Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme
- Author(s)
- Alexander, M; Rogers, J; Parakh, S; Mitchell, P; Clay, TD; Kao, S; Hughes, BGM; Itchins, M; Kong, BY; Pavlakis, N; Solomon, BJ; John, T;
- Details
- Publication Year 2024-07,Volume 54,Issue #7,Page 1087-1096
- Journal Title
- Internal Medicine Journal
- Publication Type
- Research article
- Abstract
- BACKGROUND AND AIMS: Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum-containing therapy. METHODS: Multicentre real-world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m(2) three-weekly) on an early access programme between May 2020 and December 2021. Key outcomes were clinical utilisation, efficacy and tolerability. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Outcome data were collected within the AUstralian Registry and biObank of thoRacic cAncers (AURORA). RESULTS: Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second- (83%, 38/46) or subsequent- (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high-grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six-month OS was 44% (95% confidence interval (CI): 29.0-57.1). Twelve-month OS was 15% (95% CI: 6.5-26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8-2.9) and OS was 4.5 months (95% CI: 3.5-7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0-17.2). Individuals with a longer chemotherapy-free interval prior to lurbinectedin had longer PFS and OS. CONCLUSION: This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.
- Publisher
- Wiley
- Keywords
- Humans; *Small Cell Lung Carcinoma/drug therapy; *Lung Neoplasms/drug therapy; Male; Female; Aged; *Carbolines/therapeutic use; Middle Aged; *Heterocyclic Compounds, 4 or More Rings/therapeutic use/adverse effects; Australia; Antineoplastic Agents/therapeutic use; Aged, 80 and over; Progression-Free Survival; Treatment Outcome; Adult; lurbinectedin; real‐world data; real‐world evidence; small cell lung cancer; survival outcomes
- Department(s)
- Pharmacy; Medical Oncology
- Publisher's Version
- https://doi.org/10.1111/imj.16348
- Open Access at Publisher's Site
https://doi.org/10.1111/imj.16348- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-30 06:33:42
Last Modified: 2024-07-30 06:34:36